...
首页> 外文期刊>Journal of the Chinese Medical Association: JCMA >NMP22 in transitional cell carcinoma of the urinary bladder.
【24h】

NMP22 in transitional cell carcinoma of the urinary bladder.

机译:NMP22在膀胱移行细胞癌中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Urinary bladder transitional cell carcinoma (TCC) is a common cancer encountered in the human urinary system. The detection of new and recurrent TCC of the urinary bladder was performed using nuclear matrix (NMP22) kit and compare to the urine cytology. METHODS: Ninety-two patients were included and divided to 3 groups. The first group was composed of patients for detection of recurrence of TCC of the urinary bladder in follow-up check. The second group consisted of patients who had microscopic or gross hematuria. The third group was volunteers. A urine sample was obtained from every enrolled patient. Followed by cystourethroscopy, the urine cytoloy, urine analysis and NMP 22 were performed respectively. A receiver operating characteristics (ROC) curve was constructed to determine NMP22 cutoff value for optimal sensitivity and specificity to detect bladder tumor. The data was then analyzed with Student-t test. RESULTS: ROC curve showed an optimal value of greater than 10 units per mL in differentiating positive from negative results. The sensitivity of NMP22 was 91.7% (22/24) and the specificity was 72.1% (49/68) in detection of TCC. The sensitivity and specificity of cytology were 37.5% (9/24) and 97.1% (66/68), respectively. The positive predictive values of NMP22 and cytology were 53.7% and 81.8%, individually. The false-positive rate of NMP22 was 27.9%. More sensitivity was observed in the NMP22 test with regards to high-grade and advanced-stage tumors. CONCLUSIONS: NMP22 is a highly sensitive tumor marker. However, high false positive rate and unsatisfactory positive predictive value are the drawbacks of this new tumor marker assay. There is inadequate evidence to consider total replacement of cytology with NMP22. But combination of NMP22 and cytology could be the most complete way to avoid unnecessary cystoscopic surveillance.
机译:背景:膀胱移行细胞癌(TCC)是人类泌尿系统中常见的癌症。使用核基质(NMP22)试剂盒检测膀胱新发TCC和复发性TCC,并与尿液细胞学进行比较。方法:纳入92例患者,分为3组。第一组由随访检查中检测膀胱TCC复发的患者组成。第二组包括镜下或肉眼血尿的患者。第三组是志愿者。从每个入组​​患者中获取尿液样本。膀胱镜检查后,分别进行尿液细胞仪,尿液分析和NMP 22。构建接收器操作特征(ROC)曲线以确定NMP22临界值,以最佳灵敏度和特异性检测膀胱肿瘤。然后使用Student-t检验分析数据。结果:ROC曲线显示最佳值大于10个单位/ mL,以区分阳性结果和阴性结果。在检测TCC时,NMP22的敏感性为91.7%(22/24),特异性为72.1%(49/68)。细胞学的敏感性和特异性分别为37.5%(9/24)和97.1%(66/68)。 NMP22和细胞学检查的阳性预测值分别为53.7%和81.8%。 NMP22的假阳性率为27.9%。在NMP22测试中,观察到了对高度和晚期肿瘤的更高敏感性。结论:NMP22是高度敏感的肿瘤标志物。然而,高的假阳性率和令人满意的阳性预测值是这种新的肿瘤标志物测定法的缺点。没有足够的证据考虑用NMP22完全替代细胞学。但是,将NMP22与细胞学相结合可能是避免不必要的膀胱镜检查的最完整方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号